Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Biosimilars Market Value Growth And Long-Term Outlook
The biosimilars market has experienced significant expansion recently. It is projected to expand from $21.85 billion in 2025 to $25.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.9%. Historically, this growth has been driven by factors such as the increasing incidence of chronic and autoimmune diseases, the substantial expense of original biologic drugs, a rising need for affordable treatment options, continuous innovation in biopharmaceutical research and development, and the improvement of healthcare infrastructure in developing economies.
The biosimilars market size is anticipated to experience significant expansion over the next few years. It is projected to increase to $48.52 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 17.4%. This growth during the forecast period is primarily driven by factors such as the expiration of patents for major biologics, the rising use of biosimilars in oncology and autoimmune therapies, favorable government incentives and policies, the scaling of manufacturing capabilities in the Asia-Pacific region, and an increase in partnerships between biopharma companies and contract manufacturing organizations. Noteworthy trends for this period encompass personalized biosimilar development, the manufacturing of cost-effective biologics, regulatory alignment and adherence, the expansion of biosimilar markets into emerging regions, and strategic collaborations and alliances.
Get A Free Sample Report With In-Depth Market Insights:
Biosimilars Market Growth Drivers: What’s Behind The Acceleration?
Rising healthcare expenditures are anticipated to drive the expansion of the biosimilars market moving forward. These expenditures represent the aggregate spending on medical goods and services within a particular population or healthcare system. The biosimilars market aids in decreasing healthcare spending by presenting more affordable options than expensive biologic drugs, thus reducing treatment costs for both patients and healthcare systems. For instance, in March 2024, according to the Health Foundation, a UK-based independent charity and think tank, the overall health expenditures in England for the last confirmed spending year, 2022/23, amounted to £182 billion ($196.78 billion). While planned health spending is projected to reach £192 billion ($207.59 billion) in 2024/25, inflation is expected to limit the real-term increase to merely 0.6% compared to the 2023/24 fiscal year. Hence, growing healthcare expenditures are a primary impetus for the biosimilars market’s growth.
Biosimilars Market Segment Analysis: What Are The Core Market Categories?
The biosimilars market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones
2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins
3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications
Subsegments:
1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars
2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars
3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars
4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars
5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars
Biosimilars Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies within the biosimilars market prioritize the creation of innovative products to secure a competitive advantage. FYLNETRA serves as a leukocyte growth factor, designed to reduce the occurrence of infections, specifically febrile neutropenia, in patients with non-myeloid cancers who are undergoing myelosuppressive anti-cancer drug treatments that carry a high risk of febrile neutropenia. As an illustration, in May 2023, Amneal Pharmaceuticals Inc., a pharmaceutical firm based in the US, initiated the commercial release of FYLNETRA (pegfilgrastim-pbbk), a biosimilar that references Neulasta and is available in a pre-filled single-dose syringe. FYLNETRA is employed for managing neutropenia (a condition characterized by low levels of neutrophils, a kind of white blood cell crucial for fighting infection), a common side effect for individuals receiving chemotherapy.
Biosimilars Market Top Companies Driving Competitive Growth
Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)
View The Full Biosimilars Market Report:
Biosimilars Market Geographic Distribution And Regional Opportunities
North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model